Daily Bio News Summary — 2026-08-04: Pfizer prunes its obesity pipeline, KKR takes Integer private, and Latigo sets $247M IPO terms

Today’s harvest produced 20 news items from five sources: Fierce Pharma (6), Fierce Biotech (3), BioSpace (5), STAT News (2), and PR Newswire FDA (3, with one NIPRO launch skipped as a near-duplicate of an existing clearance file). The dominant threads are portfolio pruning at big pharma, mid-stage clinical scorecards, take-private dealmaking, and a busy IPO window. One new company profile was created (Pathos AI) and ten news items carry a company reference.

Portfolio pruning and restructuring

Pfizer continued its post-COVID reshaping on two fronts: cutting an additional $2.5 billion across R&D and manufacturing (BioSpace, 2026-08-03) and dropping an obesity asset it had acquired from Metsera along with a GIPR-targeting prospect (Fierce Biotech, 2026-08-04). CEO Albert Bourla defended the company’s $7 billion bolt-on M&A strategy as peers rush to buy (BioSpace, 2026-08-04). Separately, Lisata Therapeutics is cutting 72% of its workforce and suing Kuva after their planned merger fell apart (BioSpace, 2026-08-04) — the steepest workforce reduction in today’s batch. J&J announced that Jennifer Taubert, chief of its innovative medicine division, will retire, handing the reins to its North America head (Fierce Pharma, 2026-08-04). BioNTech downgraded its sales forecast amid slumping demand for its COVID-19 vaccine (BioSpace, 2026-08-03).

Merck’s mid-stage scorecard

Two items track Merck’s clinical fortunes today. The company’s $10.8B Prometheus acquisition delivered another win — plus a Phase 2b miss — in inflammatory disease trials (BioSpace, 2026-08-04). And the FDA has made Merck’s oral PCSK9 pill Lipfendra a poster child for its CNPV pilot as Merck charts a long-term path for the first-in-class drug (Fierce Pharma, 2026-08-04).

Dealmaking and the IPO window

KKR signed a $5.7 billion deal to take medical device manufacturer Integer private (Fierce Biotech, 2026-08-04). Latigo Biotherapeutics set terms for a $247 million IPO to fund its non-opioid pain drug, a rival to Vertex’s Journavx (Fierce Biotech, 2026-08-04). And AI-enabled oncology biotech Pathos AI inked back-to-back cancer contracts with AstraZeneca and China’s Alphamab (BioSpace, 2026-08-04) — the basis for today’s new company profile.

Regulatory and legal

Otsuka’s kidney drug Voyxact stabilized kidney function decline in IgAN patients in a Phase 3 trial, a first for the indication (Fierce Pharma, 2026-08-03). Jazz Pharmaceuticals will withdraw Zepzelca from the second-line small cell lung cancer setting (Fierce Pharma, 2026-08-04), following a confirmatory trial failure. Gilead prevailed in a yearslong HIV drug innovation case after the California Supreme Court ruled drugmakers have no duty to innovate (Fierce Pharma, 2026-08-04). Bayer CEO Bill Anderson is staying the course on the company’s turnaround plan (Fierce Pharma, 2026-08-04), and Aqua Medical named Bob Haggerty CEO as it targets type 2 diabetes (PR Newswire FDA, 2026-08-04).

Public health

The Ebola outbreak in eastern Democratic Republic of Congo has killed 1,700 people, making it the fastest-growing outbreak on record (STAT News, 2026-08-04). Michigan reported the first two U.S. deaths linked to the record cyclospora outbreak (STAT News, 2026-08-03).

What this batch is NOT telling us

Several usual suspects are absent today. Endpoints News produced zero surviving items: every Endpoints candidate in the harvest showed soft-paywall copy (“sign up to read this article”) on direct verification. The Endpoints versions of the Pfizer cost-cut and Bourla-dealmaking stories were therefore replaced with free BioSpace coverage, but four stories have no free-source alternative this run and were dropped entirely: the Merck sac-TMT combo trial plan, the ambient-scribe convergence feature, Akido’s clinic AI expansion, and Bayer’s German stroke-drug launch. BioPharma Dive also yielded nothing — its homepage date format changed, making per-article dates unverifiable, so its items (Alnylam earnings, Supernus, BioNTech CEO) were skipped conservatively; most were already covered by prior days’ files. No FDA Newsroom items survived this run, and no large Phase 3 readouts or mega-cap M&A (the AstraZeneca-BMS talk and Curium-Lantheus deal were covered in prior days’ harvests).

Reading order

For limited time, the highest-signal items are: (1) the Ebola milestone update, (2) Pfizer’s obesity-asset axe, (3) the KKR-Integer take-private, (4) Merck’s Prometheus scorecard, and (5) the Lisata layoff-and-lawsuit story.

How to read the underlying articles

Each item below links out via its sourceUrl in src/content/news/; the frontmatter carries title, description, date, source, and company attribution.

1. Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges — STAT News, 2026-08-04
2. Michigan reports the first 2 U.S. deaths related to a diarrhea-causing parasite — STAT News, 2026-08-03
3. Pfizer axes ex-Metsera obesity asset and GIPR prospect — Fierce Biotech, 2026-08-04
4. Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss — BioSpace, 2026-08-04
5. Merck charts long-term path for first PCSK9 pill — Fierce Pharma, 2026-08-04
6. Gilead prevails in yearslong HIV drug innovation case — Fierce Pharma, 2026-08-04
7. Lisata axes 72% of workforce following failed merger with Kuva — BioSpace, 2026-08-04
8. Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab — BioSpace, 2026-08-04
9. KKR inks $5.7B deal to take medtech manufacturer Integer private — Fierce Biotech, 2026-08-04
10. Latigo laces up for $247M IPO to fund rival to Vertex’s Journavx — Fierce Biotech, 2026-08-04
11. J&J innovative medicine chief Jennifer Taubert to retire — Fierce Pharma, 2026-08-04
12. Bayer CEO Anderson sticking out firm’s revitalization scheme — Fierce Pharma, 2026-08-04
13. Jazz to withdraw Zepzelca in second-line small cell lung cancer — Fierce Pharma, 2026-08-04
14. Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure — BioSpace, 2026-08-03
15. Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy — BioSpace, 2026-08-04
16. In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3 — Fierce Pharma, 2026-08-03
17. BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine — BioSpace, 2026-08-03
18. New England Biolabs launches Monarch Mag Cell-free RNA (cfRNA) Extraction Kit — PR Newswire FDA, 2026-08-04
19. Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes — PR Newswire FDA, 2026-08-04
20. MellingMedical Teams Up with NIDEK USA to Advance Vision Care Technology — PR Newswire FDA, 2026-08-04